Jump to ContentJump to Main Navigation
Show Summary Details

Journal of Basic and Clinical Physiology and Pharmacology

Editor-in-Chief: Horowitz, Michal

Editorial Board Member: Das, Kusal K. / Epstein, Yoram / S. Gershon MD, Elliot / Haim, Abraham / Kodesh , Einat / Kohen, Ron / Lichtstein, David / Maloyan, Alina / Mechoulam, Raphael / Roth, Joachim / Schneider, Suzanne / Shohami, Esther / Sohmer, Haim / Yoshikawa, Toshikazu

6 Issues per year

SCImago Journal Rank (SJR) 2015: 0.302
Source Normalized Impact per Paper (SNIP) 2015: 0.474
Impact per Publication (IPP) 2015: 0.759

See all formats and pricing
Volume 25, Issue 4 (Nov 2014)


Review on treatment of premenstrual syndrome: from conventional to alternative approach

Rohit Kumar Verma
  • Department of Pharmacy Practice, School of Pharmacy, International Medical University (IMU), Kuala Lumpur, Malaysia
/ Dinesh Kumar Chellappan
  • Department of Life Sciences, School of Pharmacy, International Medical University (IMU), Kuala Lumpur, Malaysia
/ Awanish Kumar Pandey
  • Corresponding author
  • Department of Pharmacy, Institute of Technology and Management, GIDA, Gorakhpur, Uttar Pradesh, India
  • Email:
Published Online: 2014-03-12 | DOI: https://doi.org/10.1515/jbcpp-2013-0072


Premenstrual syndrome (PMS) is the most common problem associated with women’s health. Most women take alternative therapies for the treatment of PMS along with conventional therapies. A literature search was conducted which investigated various conventional and alternative therapies for the treatment of PMS. Web- and manual-based literature surveys were conducted to assess the information available on conventional and alternative treatment of PMS. Pubmed, Scopus, and Google scholar databases were screened, using the terms ‘PMS and its management’, ‘pharmacotherapy of PMS’, ‘Alternative therapies for the treatment of PMS’. Publications with abstract/full articles and books were reviewed. Based on the available literature, there have been randomized clinical trials (RCTs) and high levels of evidence studies. The review addressed that drosperinone with ethinylestradiol has shown great improvement in symptoms of PMS in various RCTs. Among the alternative therapies use of micronutrients and herbs were found effective in treatment for symptoms of PMS.

Keywords: alternative therapies; herbs; micronutrients; premenstrual syndrome


  • 1.

    Singh A, Kiran D, Singh H. Prevalence and severity of dysmenorrhea: a problem related to menstruation, among 1st and 2nd year female medical students. Indian J Physiol Pharmacol 2008;52:389–97.

  • 2.

    Edilberto AR, José CL, João PN, Ulisses M. Essential fatty acids for premenstrual syndrome and their effect on prolactin and total cholesterol levels: a randomized, double blind, placebo-controlled study. Reprod Health 2011;8:1742–55.

  • 3.

    Lisa M, Alice D, Vittorio K, Fabrizio J, Eduardo F, Maurizio T. Perimenstrual symptom prevalence rates: an Italian-American comparison. Am J Epidemiol 1993;138:1070–81.

  • 4.

    Mortola JF, Girton L, Beck L, Yen SS. Diagnosis of premenstrual syndrome by a simple, prospective, and reliable instrument: the calendar of premenstrual experiences. Obstet Gynecol 1990;76:302–7. [PubMed]

  • 5.

    Soares CN, Cohen LS, Otto MW, Harlow BL. Characteristics of women with premenstrual dysphoric disorder (PMDD) who did or did not report history of depression: a preliminary report from the Harvard Study of Moods and Cycles. J Women’s Health Gender Based Med 2001;10:873–8.

  • 6.

    Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson- Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005;106:492–501. [PubMed] [Crossref]

  • 7.

    Fathizadeh N, Ebrahimi E, Valiani M, Tavakoli N, Yar MH. Evaluating the effect of magnesium and magnesium plus vitamin B6 supplement on the severity of premenstrual syndrome. Iran J Nurs Midwifery Res 2010;15:401–5.

  • 8.

    Emans SJ, Laufer MR, Goldstein DP. Premenstrual syndrome. In: Pediatric and adolescent gynecology, 5th ed. Philadelphia, PA: Lippincott-Raven Inc., 2005:461–7.

  • 9.

    Gehlert S, Chang CH, Hartlage S. Symptom patterns of premenstrual dysphoric disorder as defined in the Diagnostic and Statistical Manual of Mental Disorders-IV. J Womens Health 1999;8:75–85. [PubMed] [Crossref]

  • 10.

    Liu W, Changzhen G. Expert advice-treatment of premenstrual syndrome in traditional Chinese medicine (TCM). The American Academy of Acupuncture and Oriental Medicine. http://www.tcmpage.com/hp_pms.html. Accessed 28 Feb 2013.

  • 11.

    Sue D. Premenstrual syndrome Evidence-based treatment in family practice. Can Fam Physician 2002;48:1789–97.

  • 12.

    Halbreich U, Smoller JW. Intermittent luteal phase sertaline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry 1997;58:399–402. [Crossref]

  • 13.

    Wyatt KM, Dimmock PW, O’Brien PM. Premenstrual syndrome. Clinical Evidence 1999;1:286–97.

  • 14.

    Ellen W, Freeman EW, Halbreich UU, Gary S, Grubb GS, Ginger D. An overview of four studies that evaluated a continuous oral contraceptive (OC) containing levonorgestrel (90 mcg) and ethinyl estradiol (20 mcg; LNG/EE) for managing premenstrual dysphoric disorder (PMDD) and premenstrual syndrome (PMS). Contraception 2012;85:437–45.

  • 15.

    Pearlstein TB, Stone AB. Long-term fluoxetine treatment of late luteal phase dysphoric disorder. J Clin Psychiatry 1994;55:332–5.

  • 16.

    Rapkin A. A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder. Psychoneuroendocrinology 2003;28:39–53. [Crossref] [PubMed]

  • 17.

    Muse KN, Cetel NS, Futterman LA, Yen SC. The premenstrual syndrome. Effects of “medical ovariectomy”. N Engl J Med 1984;311:1345–9. [Crossref]

  • 18.

    Mortola JF. Applications of gonadotropin-releasing hormone analogues in the treatment of premenstrual syndrome. Clin Obstet Gynecol 1993;36:753–63. [PubMed] [Crossref]

  • 19.

    Brown CS, Ling FW, Andersen RN, Farmer RG, Arheart KL. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet Gynecol 1994;8:779–86.

  • 20.

    Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29–38. [PubMed] [Crossref]

  • 21.

    Foidart JM, Wuttke W, Bouw GM, Gerlinger C, Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000;5:124–34. [Crossref]

  • 22.

    Apter D, Borsos A, Baumgartner W, Melis GB, Vexiau-Robert D, Colligs-Hakert A, et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care 2003;8:37–51. [PubMed] [Crossref]

  • 23.

    Sangthawan M, Taneepanichskul S. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms. Contraception 2005;71:1–7. [Crossref]

  • 24.

    Schultz-Zehden B, Boschitsch E. User experience with an oralcontraceptive containing ethinylestradiol 30 mug and drospirenone 3 mg (yasmin®) in clinical practice. Treat Endocrinol 2006;5:251–6. [Crossref]

  • 25.

    Johnson SR. Prementrual syndrome therapy. Clin Obstet Gynecol 1998;41:405–21. [Crossref]

  • 26.

    Lajoie F, Desindes S. Improving treatment for premenstrual syndrome. Can J Med 2002;81–93.

  • 27.

    Shabnam M. Non pharmacological treatment of premenstrual syndrome. Afr J Midwifery Womens Health 2011;5:148–52.

  • 28.

    Clare S, Edzard E. Complementary/alternative therapies for premenstrual syndrome: a systematic review of randomized controlled trials. Am J Obstet Gynecol 2001;185:227–35.

  • 29.

    National Institutes of Health. National centre for complementary and alternative medicine web site. Available at: http://nccam.nih.gov. Accessed 29 Nov 2006.

  • 30.

    Kessler RC, Davis RB, Foster DF, Van Rompay MI, Walters EE, Wilkey SA, et al. Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Int Med 2001;135:262–8. [Crossref]

  • 31.

    Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, et al. Trends in alternative medicine use in the United States, 1990–1997: results of a follow up national survey. J Am Med Assoc 1998;280:1569–75.

  • 32.

    Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med 1993;328:246–52.

  • 33.

    Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Adv Data 2004;(343):1–19.

  • 34.

    Harris P, Rees R. The prevalence of complementary and alternative medicine use among the general population: a systematic review of the literature. Complemen Ther Med 2000;8:88–96. [Crossref]

  • 35.

    Fisher P, Ward A. Complementary medicine in Europe. Br Med J 1994;309:107–11.

  • 36.

    Haertel U, Volger E. Use and acceptance of classical natural and alternative medicine in Germany – findings of a representative population-based survey. Forsch Komplementarmed Klass Naturheilkd 2004;11:327–34.

  • 37.

    MacLennan AH, Wilson DH, Taylor AW. The escalating cost and prevalence of alternative medicine. Prev Med 2002;35:166–73. [Crossref]

  • 38.

    Minton JP, Foecking MK, Webster DJ. Caffeine, cyclic nucleotides and breast disease. Surgery 1979;86:105.

  • 39.

    Bryant M, Cassidy A, Hill C, Powell J, Talbot D, Dye L. Effect of consumption of soy isoflavones on behavioural, somatic and affective symptoms in women with premenstrual syndrome. Br J Nutr 2005;93:731–9. [Crossref]

  • 40.

    Lam RW, Carter D, Misri S, Kuan AJ, Yatham LN, Zis AP. A controlled study of light therapy in women with late luteal phase dysphoric disorder. Psychiatry Res 1999;86:185–92. [Crossref]

  • 41.

    Oleson T, Flocco W. Randomized controlled study of premenstrual symptoms treated with ear, hand, and foot reflexology. Am J Obstet Gynecol 1993;82:906–11.

  • 42.

    Howlett T, Grossman A. Oxford textbook of sports medicine. England, Oxford: Oxford University Press, 1996:276–82.

  • 43.

    Gannon L. The potential role of exercise in the alleviation of menstrual disorders and menopausal symptoms: a theoretical synthesis of recent research. Women Health 1988;14:105–27. [Crossref]

  • 44.

    Greene JV. Exercise-induced menstrual irregularities. Compr Ther 1993;19:116–20.

  • 45.

    Steege JF, Blumenthal JA. The effects of aerobic exercise on premenstrual symptoms in middle-aged women: a preliminary study. J Psychosom Res 1993;37:127–33. [Crossref]

  • 46.

    Aganoff JA, Boyle GJ. Aerobic exercise, mood states and menstrual cycle symptoms. J Psychosom Res 1994;38:183–92. [Crossref]

  • 47.

    Barnhart KT, Freeman EW, Sondheimer SJ. A clinician’s guide to the premenstrual syndrome. Med Clin North Am 1995;79:1457–72.

  • 48.

    Choi PY, Salmon P. Symptom changes across the menstrual cycle in competitive sportswomen, exercisers and sedentary women. Br J Clin Psychol 1995;34:447–60. [Crossref]

  • 49.

    Horrobin DF, Manku MS, Brush M, Callender K, Preece PE, Mansel RE. Abnormalities in plasma essential fatty acid levels in women with premenstrual syndrome and with non-malignant breast disease. J Nutr Environ Med 1991;2:259–64. [Crossref]

  • 50.

    Brush M, Watson J, Horrobin D, Manku MS. Abnormal essential fatty acid levels in plasma of women with premenstrual syndrome. Am J Obstet Gynecol 1984;150:363–6.

  • 51.

    Gateley CA, Maddox PR, Pritchard GA, Sheridan W, Harrison BJ, Pye JK, et al. Plasma fatty acid profiles in benign breast disorders. Br J Surg 1992;79:407–9. [Crossref]

  • 52.

    Cameron I, Fraser I, Smith S. Clinical disorders of the endometrium and menstrual cycle. Oxford: Oxford University Press, 1998.

  • 53.

    Brush MG. Evening primrose oil in the treatment of premenstrual syndrome. In: Horrobin DF, editor. Clinical uses of essential fatty acids. Montreal: Eden Press, 1982:155–62.

  • 54.

    Somers J, Querée M. Core information document on cognitive-behavioural therapy was developed by the Centre for Applied Research in Mental Health and Addiction (CARMHA) at Simon Fraser University under the direction of the Mental Health and Addiction Branch, Ministry of Health. March 2007.

  • 55.

    Blake F, Salkovskis P, Gath D, Day A, Garrod A. Cognitive therapy for premenstrual syndrome: a controlled trial. J Psychosom Res 1998;45:307–18. [Crossref]

  • 56.

    Connolly M. Premenstrual syndrome: an update on definitions, diagnosis and management. Adv Psychiatr Treat 2001;7:469–77. [Crossref]

  • 57.

    Thys-Jacobs S. Micronutrients and the premenstrual syndrome: the case for calcium. J Am Coll Nutr 2000;19:220–7. [Crossref]

  • 58.

    Thys-Jacobs S, Ceccarelli S, Bierman A, Weisman H, Cohen MA, Alvir J. Calcium supplementation in premenstrual syndrome. J Gen Intern Med 1989;4:183–9. [Crossref]

  • 59.

    Penland JG, Johnson PE. Dietary calcium and manganese effects on menstrual cycle symptoms. Am J Obstet Gynecol 1993;168:1417–23. [Crossref]

  • 60.

    Thys-Jacobs S, Starkey P, Bernstein D, Tian J. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Am J Obstet Gynecol 1998;179:444–52. [Crossref]

  • 61.

    Muneyvirci-Delale O, Nacharaju VL, Altura BM, Altura BT. Sex steroid hormones modulate serum ionized magnesium and calcium levels throughout the menstrual cycle in women. Fertil Steril 1998;69:958–62.

  • 62.

    Sherwood RA, Rocks BF, Stewart A, Saxton RS. Magnesium and the premenstrual syndrome. Ann Clin Biochem 1986;23:667–70. [Crossref]

  • 63.

    Rosenstein DL, Elin RJ, Hosseini JM, Grover G, Rubinow DR. Magnesium measures across the menstrual cycle in premenstrual syndrome. Biol Psychiatry 1994;35:557–61. [Crossref]

  • 64.

    Abraham GE, Lubran MM. Serum and red cell magnesium levels in patients with premenstrual tension. Am J Clin Nutr 1981;34:2364–6.

  • 65.

    Facchinetti F, Borella P, Valentini M, Fioroni L, Genazzani AR. Premenstrual increase of intracellular magnesium levels in women with ovulatory, asymptomatic menstrual cycles. Gynecol Endocrinol 1988;2:249–56. [Crossref]

  • 66.

    Facchinetti F, Borella P, Pironti T, Genazzani AR. Reduction of monocyte magnesium in patients affected by premenstrual syndrome. J Psychosom Obstet 1990;11:221–9. [Crossref]

  • 67.

    Mira M, Stewart PM, Abraham SF. Vitamin and trace element status in premenstrual syndrome. Am J Clin Nutr 1988;47: 636–41.

  • 68.

    Posaci C, Erten O, Uren A, Acar B. Plasma copper, zinc and magnesium levels in patients with premenstrual tension syndrome. Acta Obstet Gynecol Scand 1994;73:452–5. [Crossref]

  • 69.

    Bendich A. The potential for dietary supplements to reduce premenstrual syndrome (PMS) symptoms. J Am Coll Nutr 2000;19:3–12. [Crossref]

  • 70.

    Walker AF, De Souza MC, Vickers MF, Abeyasekera S, Collins ML, Trinca LA. Magnesium supplementation alleviates premenstrual symptoms of fluid retention. J Womens Health 1998;7:1157–65. [Crossref]

  • 71.

    Facchinetti F, Borella P, Sances G, Fioroni L, Nappi RE, Genazzani AR. Oral magnesium successfully relieves premenstrual mood changes. Obstet Gynecol 1991a;78:177–81.

  • 72.

    Facchinetti F, Sances G, Borella P, Genazzani AR, Nappi G. Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache 1991b;31:298–301. [Crossref]

  • 73.

    Premenstrual Syndrome Studies from G. Ozgoli and co-researchers in the area of premenstrual syndrome published. Anonymous. OBGYN & Reproduction Week. Atlanta 28, 2009;45.

  • 74.

    Facchinetti F, Dante G, Bitzer J. Attitude toward premenstrual syndrome (changes): an international survey. J Psychosom Obstet 2007;28:S21–50.

  • 75.

    Tong IL. Non-pharmacological treatment of postmenopausal symptoms. Obstet Gynecol 2013;15:19–25. [Crossref]

  • 76.

    Schulz V, Hansel R, Tyler VE. Gynecologic indications for herbal remedies. In: Rational phytotherapy, a physicians’ guide to herbal medicine. Berlin: Springer-Verlag, 1998.

  • 77.

    Snow JM. Vitex agnus-castus L. (Verbenaceae). Protocol J Bot Med 1996;1:20–3.

  • 78.

    Hobbs C. Vitex: the women’s herb. Santa Cruz (CA). Botanicas en el Directorio de Puerto Rico, 1996.

  • 79.

    Roemheld-Hamm B. Chasteberry. Am Fam Phys 2005;72:821–4.

  • 80.

    Gorkow C, Wuttke W, Marz RW. Effectiveness of vitex agnus castus preparations. Wiener Medizinische Wochenschrift 2002;152:364–72. [Crossref]

  • 81.

    Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: Prospective, randomized, placebo controlled study. Br Med J 2001;322:134.

  • 82.

    Ma L, Lin S, Chen R, Wang X. Treatment of moderate to severe premenstrual syndrome with vitex agnus castus (BNO, 1095) in Chinese women. Gynecol Endocrinol 2010;26:612–6.

  • 83.

    Rios JL, Redo MC, Giner RM, Manez S. An update review of saffron and its active constituents. Phytother Res 1996;10:189–93. [Crossref]

  • 84.

    Agha-Hosseini M, Kashani L, Aleyaseen A, Ghoreishi A, Rahmanpour H, Zarrinara AR, et al. Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo controlled trial. Br J Obstet Gynaecol 2008;115:515–9. [Crossref]

About the article

Corresponding author: Awanish Kumar Pandey, Department of Pharmacy, Institute of Technology and Management, GIDA, Gorakhpur, Uttar Pradesh, India, 273209, E-mail:

Received: 2013-05-22

Accepted: 2014-01-17

Published Online: 2014-03-12

Published in Print: 2014-11-01

Citation Information: Journal of Basic and Clinical Physiology and Pharmacology, ISSN (Online) 2191-0286, ISSN (Print) 0792-6855, DOI: https://doi.org/10.1515/jbcpp-2013-0072. Export Citation

Comments (0)

Please log in or register to comment.
Log in